|Bid||81.02 x 800|
|Ask||81.62 x 3200|
|Day's Range||81.12 - 81.94|
|52 Week Range||58.03 - 83.85|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||25.63|
|Forward Dividend & Yield||2.20 (2.80%)|
|1y Target Est||N/A|
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells.
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
American pharmaceutical giant Merck & Co. said it is buying Peloton Therapeutics, a clinical-stage biopharmaceutical company, for $1.05 billion in cash.
Roche Holding AG (RHHBY) has climbed 2.4% over the last week, 0.5% over the past month, 5.7% so far this year, 17.6% over the last 52 weeks and 5.3% over the past three years through May 20. Warning! GuruFocus has detected 3 Warning Signs with RHHBY. Currently, the company is paying an annual dividend of $1.07 per common share, which, based on the closing share price on May 20, leads to a forward dividend yield of 3.27% versus the industry median of 1.66%.
DFW company, had filed to go public less than a month ago, could see shareholders get additional $1.15 billion
The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio. Merck's blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer.
Merck will pay $1.05 billion in cash, plus $1.15 billion in additional payments based on how the small company’s experimental drugs fare as they are developed further by Merck, the firms said in a statement announcing the deal Tuesday. The deal offers an immediate payout for Peloton’s investors, including Dallas-based venture capital firm Remeditex Ventures and San Francisco’s The Column Group. At the $17 high range of Peloton’s expected initial public offering, the market would have valued the company at $756 million.
Merck & Co., Inc. (NYSE: MRK ) announced an agreement Tuesday to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion in ...
on Tuesday said it agreed to buy privately held Peloton Therapeutics for about $1 billion in cash, giving it access to Peloton's molecular therapy biotech treatments currently in development for patients with cancer and other non-oncology diseases. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Peloton in exchange for an upfront payment of $1.05 billion in cash, the company said. Peloton shareholders also will be eligible to receive a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.
Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion.
Merck & Co. Inc. said Tuesday it has reached an agreement to acquire Peloton Therapeutics Inc. for an upfront payment of $1.05 billion in cash. Peloton, a clinical-stage biotech focused on cancer treatments, was expected to price an initial public offering on Wednesday. The biotech's business hinges instead on two drugs that are designed to block a transcription factor called hypoxia-inducible factor-2 alphaαthat - among other things - regulates how the body responds to low oxygen levels. Under the terms of the deal, Peloton shareholders will be entitled to a further $1.15 billion in milestone payments based on the achievement of certain future regulatory and sales goals. "This acquisition exemplifies Merck's strategy to pursue novel therapeutic candidates based on exceptionally promising and innovative research," said Dr. Roger M. Perlmutter, president of Merck Research Laboratories. "Peloton scientists have applied their unique expertise in HIF-2α biology to develop PT2977, which has already shown intriguing activity in the treatment of renal cell carcinoma. We look forward to advancing this late-stage asset as part of our broad oncology R&D program." The deal is expected to close in the third quarter. Merck shares were not active premarket, bu have gained 34.7% in the last 12 months, while the S&P 500 has gained 3.9%.
Shares of Merck & Co MRK dropped as much as 9% in extended trading on Monday, before erasing those losses, after the pharmaceutical company announced that its medication Keytruda failed to meet expectations in phase 3 of the drug's trial. Shares of Snap SNAP ticked slightly higher after the company announced it has named a new chief financial officer to take over for interim CFO Lara Sweet, effective immediately. The social media company promoted Derek Andersen, Snap's current vice president of finance, to permanently fill the position of chief financial officer.
Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer. Keytruda, among a class of medicines called PD-1 inhibitors, did not meet the main goal of helping patients live longer, when compared to chemotherapy. The treatment will continue to be studied in earlier stages of the disease and in combination with chemotherapy in patients with triple negative breast cancer, the company said.
Merck & Co. shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in another late-stage study. Merck shares declined 0.7% after hours, following a 0.2% rise to close the regular session at $78.88. In a Phase 3 clinical study, Merck said Keytruda "did not meet its pre-specified primary endpoint of superior overall survival" compared with chemotherapy in a subset of breast cancer patients. In late April, Merck said Keytruda did not show significant improvement over chemotherapy in gastric cancer patients. For the year, Merck shares are up 3.2%, compared with a 13.3% rise in the S&P 500 index .
The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision to let the lawsuits proceed even though the Food and Drug Administration had rebuffed Merck when the company sought to add a warning to Fosamax's label about fracture risk.